Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 2/20 | 0.64 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999376 | 0.92 | MLNR (0.54) | MLNRGPR119TGFBR1HDAC1LMNA | |
| SCHEMBL2849659 | 0.89 | MLNR (0.70) | MLNRLMNARORCTP53MAPT | |
| SCHEMBL1996928 | 0.88 | GPR119 (0.49) | MLNRGPR119TGFBR1RORC | |
| SCHEMBL1998342 | 0.83 | MLNR (0.49) | MLNRGPR119 | |
| SCHEMBL1995197 | 0.83 | MLNR (0.63) | MLNRGPR119TGFBR1 | |
| SCHEMBL2003276 | 0.83 | MLNR (0.49) | MLNRGPR119 | |
| SCHEMBL1995581 | 0.82 | MLNR (0.62) | MLNRLMNATP53MAPTPOLB | |
| SCHEMBL2849480 | 0.81 | MLNR (0.58) | MLNRLMNAMAPTPOLB | |
| SCHEMBL2002043 | 0.81 | MLNR (0.46) | MLNRGPR119TGFBR1 | |
| SCHEMBL1997045 | 0.80 | MLNR (0.48) | MLNRGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964597-B2 | Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| US-7964597-B2 | Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD. | 2010-10-07 | — | — | US | disclosed |
| WO-2009068552-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GPR68, GPR88, GIPR | MLNR 12/4885GPR119 4/4885TGFBR1 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.